PTC Therapeutics, Inc. (PTCT)
| Market Cap | 6.52B +70.9% |
| Revenue (ttm) | 827.11M -53.3% |
| Net Income | -186.73M |
| EPS | -2.32 |
| Shares Out | 82.95M |
| PE Ratio | n/a |
| Forward PE | 106.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 704,130 |
| Open | 77.52 |
| Previous Close | 78.52 |
| Day's Range | 77.47 - 79.41 |
| 52-Week Range | 43.18 - 90.87 |
| Beta | 0.53 |
| Analysts | Buy |
| Price Target | 95.93 (+22.06%) |
| Earnings Date | Jul 30, 2026 |
About PTCT
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for PTCT stock is "Buy." The 12-month stock price target is $95.93, which is an increase of 22.06% from the latest price.
News
PTC Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, July 30, 2026
WARREN, N.J., July 16, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its second quarter 2026 financial resul...
PTC Therapeutics price target raised to $130 from $124 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on PTC Therapeutics (PTCT) to $130 from $124 and keeps an Overweight rating on the shares. The firm says its analysis showcases that…
PTC Therapeutics price target raised to $95 from $93 at BofA
BofA raised the firm’s price target on PTC Therapeutics (PTCT) to $95 from $93 and keeps a Buy rating on the shares. The firm, which conducted a survey of 20…
PTC Therapeutics price target raised to $91 from $89 at JPMorgan
JPMorgan raised the firm’s price target on PTC Therapeutics (PTCT) to $91 from $89 and keeps an Overweight rating on the shares ahead of the Q2 report. The firm updated…
PTC Therapeutics price target raised to $85 from $82 at RBC Capital
RBC Capital raised the firm’s price target on PTC Therapeutics (PTCT) to $85 from $82 and keeps a Sector Perform rating on the shares as part of a broader research…
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., June 17, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 11, 2026, the company approved non-statutory stock options to purchase an aggregate of 10...
PTC Therapeutics Announces Pricing of Convertible Notes Offering to Refinance 2026 Convertible Notes
– Refinancing transaction with proceeds to be utilized to repurchase or repay the 2026 convertible notes prior to or at maturity – – Offering made at 0% interest with conversion price of $107.48, a 40...
PTC Therapeutics files to sell $500M of Convertible Senior Notes due 2031
PTC Therapeutics (PTCT) announced that it intends to offer $500M aggregate principal amount of Convertible Senior Notes due 2031 to qualified institutional buyers pursuant to Rule 144A under the Secur...
PTC Therapeutics Announces Proposed Convertible Notes Offering to Refinance 2026 Convertible Notes
– Proceeds to be used to repurchase or repay 2026 convertible notes prior to or at maturity – – Offering to include buyback of common stock – WARREN, N.J., June 15, 2026 /PRNewswire/ -- PTC Therapeuti...
PTC Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Record revenue growth driven by SEPHIENCE's global launch, with broad patient uptake and strong market expansion. Pipeline advances include new trials for vatiquinone, NLRP3, and DHODH compounds, while financial discipline and a robust cash position support ongoing business development and profitability.
PTC Therapeutics assumed with Buy from Neutral at Citi
Citi upgraded PTC Therapeutics (PTCT) to Buy from Neutral with a price target of $108, up from $75, after assuming coverage of the name. The firm cites its bullish outlook…
PTC Therapeutics Transcript: AGM 2026
The meeting confirmed a quorum, elected four directors, ratified the auditor, and approved executive compensation, with all proposals passing by large majorities. No questions were submitted by stockholders, and forward-looking statements were accompanied by risk disclaimers.
PTC Therapeutics upgraded to Buy from Hold at Jefferies
Jefferies upgraded PTC Therapeutics (PTCT) to Buy from Hold with a price target of $85, up from $76. The firm’s deep dive, which includes a new patient build model, suggests…
PTC Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026
Sephience’s launch is exceeding expectations with broad U.S. and international uptake, driven by strong clinical benefits and a robust commercial strategy. Financial guidance has been raised, and pipeline programs in Huntington’s and rare diseases are advancing, supported by a strong balance sheet.
PTC Therapeutics Transcript: Bank of America Global Healthcare Conference 2026
Strong SEPHIENCE launch drove significant revenue growth, with broad patient uptake and sustained momentum in the U.S. and internationally. Robust R&D progress includes a pivotal Huntington's disease trial with Novartis and a solid financial position to support future expansion.
PTC Therapeutics price target raised to $89 from $80 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on PTC Therapeutics (PTCT) to $89 from $80 and keeps an Overweight rating on the shares. The firm updated the company’s…
PTC Therapeutics Slides: Corporate presentation
PTC Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on May 10, 2026.
PTC Therapeutics price target raised to $94 from $92 at Morgan Stanley
Morgan Stanley analyst Judah Frommer raised the firm’s price target on PTC Therapeutics (PTCT) to $94 from $92 and keeps an Overweight rating on the shares.
PTC Therapeutics upgraded to Buy from Hold at TD Cowen
TD Cowen upgraded PTC Therapeutics (PTCT) to Buy from Hold with a price target of $90, up from $75. The company’s 2026 product revenue guidance was raised on the back…
PTC Therapeutics reports Q1 EPS (3c) vs. ($10.04) last year
Reports Q1 revenue $273M, consensus $225.35M. “We are off to a strong start to 2026 with outstanding revenue performance this quarter that supports raising our full-year product revenue guidance,” sai...
PTC Therapeutics raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
16:10 EDT PTC Therapeutics (PTCT) raises 2026 revenue view to $1.08B-$1.18B, consensus $990.78M
PTC Therapeutics Earnings Call Transcript: Q1 2026
Record Q1 revenue driven by Sephience's strong global launch led to raised 2026 guidance. U.S. remains the main growth driver, with international expansion accelerating and robust payer coverage supporting broad adoption.
PTC Therapeutics Earnings release: Q1 2026
PTC Therapeutics released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
PTC Therapeutics Quarterly report: Q1 2026
PTC Therapeutics has published its Q1 2026 quarterly earnings report on May 7, 2026.
PTC Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results
– First quarter 2026 total revenue of $273 million, including $226 million of product revenue, supporting full-year 2026 guidance raise – – Global Sephience™ (sepiapterin) launch momentum continues...